New hope for hard-to-treat blood cancer: DREAMM 7 trial compares two drug combos
NCT ID NCT06868654
First seen Apr 26, 2026 · Last updated May 23, 2026 · Updated 4 times
Summary
This phase 3 study tests whether a new drug combination (belantamab mafodotin plus bortezomib and dexamethasone) works better than a standard combination (daratumumab plus bortezomib and dexamethasone) for people with multiple myeloma that has come back or stopped responding to treatment. About 72 Chinese participants will be enrolled. The main goal is to see how long the cancer stays under control before it progresses again.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Beijing, China
-
GSK Investigational Site
Changchun, China
-
GSK Investigational Site
Guangzhou, China
-
GSK Investigational Site
Hangzhou, China
-
GSK Investigational Site
Jinan, China
-
GSK Investigational Site
Nanjing, China
-
GSK Investigational Site
Shenyang, China
-
GSK Investigational Site
Suzhou, China
-
GSK Investigational Site
Tianjin, China
-
GSK Investigational Site
Wuhan, China
-
GSK Investigational Site
Zhengzhou, China
Conditions
Explore the condition pages connected to this study.